NCT02834611: Ceramide NanoLiposome in Patients With Advanced Solid Tumors

NCT02834611
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled active central nervous system (CNS) metastases that require treatment; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT02834611

Comments are closed.

Up ↑